Professor Robin Feldman

In one fell swoop, the FTC has drastically changed the landscape of drug pricing. For decades, PBM middle players have stood at the center of the drug delivery system, structuring secret deals that drive prices higher for everyone. The FTC-PBM settlement is the culmination of years of work from both Republican and Democratic administrations, as well as persistent pressure from congressional corners. The deal is not perfect. But it is an enormous step towards rationalizing an enormously inefficient market. ftc.gov/system/files/f…

The Bottom Line: Reducing excessive market concentration leads to increased competition and lower costs.

Reintroducing competition would be good for everyone in Tennessee. No entity should have the power to hold the state hostage.

Some of the biggest pharmacy benefit managers [PBMs] (drug-pricing middlemen) also own the pharmacies that fill prescriptions. A new Tennessee bill, SB 2040, aims to change that. bit.ly/4sGGA3M

Platforms will be tempted to block agents because agents threaten the power of platforms. But in tech, you move forward or you die. Smart social media and platforms will find ways to embrace and thrive with AI agents.

Should platforms be allowed to block customers from using AI agents to make purchases? Whatever concerns we may have about agents, this particular flavor of the issue comes down to consumer rights. If your executive assistant can buy something on Amazon, why not a computerized assistant?   cnbc.com/2026/03/10/ama…

But the question highlights a broader issue: with crucial drugs, if we can’t quickly pivot to a domestic alternative, other nations can threaten to cut us off at the knees. All of this reinforces the importance of fostering US industry and US competitiveness.

I was recently asked whether it would be possible for Denmark to use Ozempic in a U.S. trade war. My answer was that no country wants to commit economic suicide by undermining their own major export. Restricting access to Ozempic could result in patients shifting to Zepbound (made by Eli Lilly—a U.S. company). That reality blunts the threat of a trade war.

The spotlight should turn to the Health Plans now. The door is open and the question is whether health plans will act in the best interests of their patients or find new ways to distort the system.

In one fell swoop, the FTC has drastically changed the landscape of drug pricing. For decades, PBM middle players have stood at the center of the drug delivery system, structuring secret deals that drive prices higher for everyone. The FTC-PBM settlement is the culmination of years of work from both Republican and Democratic administrations, as well as persistent pressure from congressional corners. The deal is not perfect. But it is an enormous step towards rationalizing an enormously inefficient market. ftc.gov/system/files/f…

1.5 million* AI agents are talking to each other on Moltbook, a social media platform exclusively for them. And startlingly, they behave a lot like us. We know social media can have negative externalities for humans—so will it drive AI agents crazy too? #footnote-2-186286950" target="_blank" rel="nofollow noopener">astralcodexten.com/p/best-of-molt… (*Source for 1.5 million: archive.ph/eDNxn - The Economist)

@ProfRobnFeldman: "The law evolves when legal minds seek out the interstices in the doctrine, the spaces where something hasn't been decided, and there is room to make an argument for the client. AI, in its current form, can never do that." dailyjournal.com/articles/389161

We need to make it clear that PBMs have a duty to the plans and patients they represent. For my money, I want the person negotiating for me ​to think about my interests, not the interests of the drug companies who are paying them on the side.  With California's SB 41 and the case PCMA v. Bonta et al, the courts have an opportunity to uphold this basic principle. news.bloomberglaw.com/health-law-and…

The "Mickey Mouse" deal between Disney and OpenAI reminds me of the Sorcerer's Apprentice from the movie Fantasia--a lot of mopping and water going back and forth, but it's not clear anything significant is going on. bloomberg.com/news/videos/20…

In the AI era, verification is the key, with the focus on verifying sources and methods, not content—see my reasoning published with the Forbes Technology Council. I believe absolute truth exists; I just don’t trust anyone to tell me what it is. forbes.com/councils/forbe…

AI companies are using shadow sites to train AI agents. As I discussed with Cade Metz of NYT, some companies are shooting first and asking questions later. The field is expanding faster than the legal system can track; some decisions may wind up biting the companies making them. nytimes.com/2025/12/02/tec…